Congestive Heart Failure
Conditions
Keywords
Acute decompensated heart failure, Double blind study,, BAY58-2667, Soluble guanylate cyclase activator
Brief summary
The purpose of this study is to assess a dose titration scheme, of a new drug (BAY58-2667) given intravenously, to evaluate if this is safe and can help to improve the well-being, symptoms (e.g. breathing) and outcome of decompensated heart failure. Patients living with chronic heart failure have a risk of increased number of hospitalisations because of worsening of their condition (decompensated heart failure). The current treatment of acute heart failure consists of oxygen and medical treatment with vasodilators and positive inotropic agents (drugs, which should strengthen the pump function of the heart) which have their limitations. Therefore there is a need for new drugs in treatment of acute heat failure.
Interventions
DRUGPlacebo
Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with decompensated chronic congestive heart failure, NYHA functional class III-IV, either ischemic or non-ischemic, requiring hospitalization, and with clinical indication for parenteral pharmacotherapy and invasive hemodynamic monitoring (i.e indwelling Swan-Ganz pulmonary artery catheter) and PCWP \>/= 18 mmHg. * Patients must have the clinical diagnosis of CHF made at least 3 month prior to enrollment. * Male or female patients, age 18 years or more.
Exclusion criteria
* Females of child-bearing potential. * Acute de-novo heart failure. * Acute myocardial infarction and/or myocardial infarction within 30 days. * Valvular heart disease requiring surgical intervention during the course of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy outcome measure will be the change of pulmonary capillary wedge pressure (PCWP) from baseline to 8 hours versus placebo. | 8 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life | Up to 30 days Follow-up | — |
| Rehospitalization | Up to 30 days Follow-up | — |
| Other hemodynamic measurements | Up to 48 hours | Right atrial pressure (RAP); mean pulmonary artery pressure (PAP mean); pulmonary artery systolic pressure (PASP); pulmonary artery diastolic pressure (PADP); cardiac output (CO); cardiac index (CI); mean arterial pressure (MAP); pulmonary vascular resistance (PVR); pulmonary vascular resistance index (PVRI); systemic vascular resistance (SVR); and systemic vascular resistance index (SVRI） |
| Safety variables | Up to 30 days follow up | Treatment-emergent adverse events, laboratory parameters, renal function, in-hospital mortality, length of stay at intensive care unit, and 30-day mortality / morbidity. |
| Plasma concentrations | During both the titration and maintenance phases were evaluated. | — |
Countries
Canada, Croatia, Czechia, Estonia, Germany, Hungary, Israel, Italy, Lithuania, Poland, Russia, Serbia, Slovenia, Spain, Sweden, United Kingdom, United States
Outcome results
None listed